GLP-1 drug extends lifespan in mice
GLP-1 drugs are known for weight loss. But new research shows they also extend lifespan in mice. That raises questions about what these drugs do in the ageing body.
GLP-1 receptor agonists are drugs that activate the glucagon-like peptide-1 receptor. They are already widely used for diabetes and obesity. The study, published in Nature Aging, now shows that treatment with such a drug meaningfully extended median lifespan in mice.
What these drugs do in the body
GLP-1 receptors are not only found in the pancreas. They also appear in the heart, brain, and immune cells. This may explain why the effect extends beyond blood sugar or body weight. The researchers suggest multiple mechanisms are active simultaneously, though the precise pathway has not yet been established.
Earlier research had already pointed to beneficial effects on inflammatory processes and the formation of new blood vessels. In this mouse study, both factors emerged as possible explanations for the extended lifespan. Whether this applies to humans cannot be concluded from this research alone.
From mice to humans: caution required
Results in mice do not automatically translate to humans. Mice age differently and respond to drugs via distinct physiological pathways. The authors emphasise that clinical studies are needed to determine whether GLP-1 agonists also affect lifespan or healthspan in people.
From a longevity perspective, this finding is nonetheless notable. GLP-1 agonists are already approved and relatively well-studied drugs. If follow-up research in humans shows a similar signal, that could accelerate the development of new applications. For now, however, this remains a promising mouse result.
Search terms to explore further: GLP-1 receptor agonist lifespan extension, inflammaging mouse model, glucagon-like peptide-1 healthspan